Trademark: 79376166
Word
LENTINEXT
Status
Pending
Status Code
681
Status Date
Monday, June 3, 2024
Serial Number
79376166
Mark Type
4
Filing Date
Thursday, June 22, 2023
Published for Opposition
Tuesday, July 9, 2024

Trademark Owner History

Classifications
5 Gene transfer agents for preventing and treating human vector-borne diseases; biological preparations, namely, biological vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations, namely, biological recombinant vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations for gene recombination for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); nucleic acids for medical, medicinal or veterinary purposes; biopharmaceuticals for the treatment of auto-immune diseases; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; reagents for use in medical genetic testing; pharmaceutical preparations for gene therapy and diagnosis of auto-immune diseases and cancer; pharmaceutical preparations for the diagnosis and the treatment of auto-immune diseases; anti-cancer preparations; antibiotics; anti-viral agents; anti-infectives; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer cells; cells for medical purposes
LENTI NEXT

Trademark Events
Aug 11, 2023
New Application Office Supplied Data Entered
Mar 11, 2024
Assigned To Examiner
Aug 10, 2023
Sn Assigned For Sect 66a Appl From Ib
Aug 15, 2023
Application Filing Receipt Mailed
Mar 15, 2024
Non-Final Action Written
Apr 23, 2024
Refusal Processed By Ib
Mar 16, 2024
Non-Final Action (Ib Refusal) Prepared For Review
Apr 3, 2024
Refusal Processed By Mpu
Apr 3, 2024
Non-Final Action Mailed - Refusal Sent To Ib
May 9, 2024
Teas/Email Correspondence Entered
May 9, 2024
Teas Response To Office Action Received
May 30, 2024
Notification Of Examiners Amendment E-Mailed
May 30, 2024
Approved For Pub - Principal Register
May 30, 2024
Examiners Amendment E-Mailed
May 30, 2024
Examiners Amendment -Written
May 30, 2024
Examiner's Amendment Entered
Jun 19, 2024
Notification Of Notice Of Publication E-Mailed
May 9, 2024
Correspondence Received In Law Office

Trademark Alertz updated from USPTO on 2030-01-24